Total Payments
$113,635
2024 Payments
$7,325
Companies
31
Transactions
282
Medicare Patients
1,854
Medicare Billing
$483,495
Payment Breakdown by Category
Research$99,410 (87.5%)
Food & Beverage$5,831 (5.1%)
Consulting$4,235 (3.7%)
Travel$4,061 (3.6%)
Other$81.15 (0.1%)
Education$17.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $99,410 | 15 | 87.5% |
| Food and Beverage | $5,831 | 245 | 5.1% |
| Consulting Fee | $4,235 | 3 | 3.7% |
| Travel and Lodging | $4,061 | 14 | 3.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $81.15 | 4 | 0.1% |
| Education | $17.00 | 1 | 0.0% |
Payments by Type
Research
$99,410
15 transactions
General
$14,225
267 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $86,835 | 28 | $0 (2020) |
| Eli Lilly and Company | $12,894 | 7 | $0 (2024) |
| Eisai Inc. | $8,517 | 42 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,685 | 5 | $0 (2024) |
| Biogen, Inc. | $634.87 | 11 | $0 (2024) |
| UCB, Inc. | $437.50 | 25 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $430.24 | 35 | $0 (2019) |
| GENZYME CORPORATION | $366.75 | 21 | $0 (2019) |
| EMD Serono, Inc. | $231.19 | 11 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $198.90 | 13 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,325 | 8 | Eli Lilly and Company ($5,339) |
| 2023 | $705.72 | 7 | Biogen, Inc. ($268.53) |
| 2022 | $9,105 | 21 | Eli Lilly and Company ($5,001) |
| 2021 | $4,340 | 3 | Eli Lilly and Company ($2,291) |
| 2020 | $160.42 | 9 | Adamas Pharmaceuticals, Inc. ($35.04) |
| 2019 | $2,317 | 81 | Eisai Inc. ($1,341) |
| 2018 | $68,596 | 72 | ACADIA Pharmaceuticals Inc ($66,923) |
| 2017 | $21,087 | 81 | ACADIA Pharmaceuticals Inc ($19,779) |
All Payment Transactions
282 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $65.99 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,339.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 07/30/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $124.26 | General |
| Category: Neurology | ||||||
| 07/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $94.58 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $942.97 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $328.37 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $308.03 | General |
| 02/07/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $121.84 | General |
| Category: Neurology | ||||||
| 10/26/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $130.39 | General |
| 10/26/2023 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $72.09 | General |
| Category: Neurology | ||||||
| 09/27/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $111.71 | General |
| Category: Neurology | ||||||
| 07/18/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $66.05 | General |
| 07/16/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $62.68 | General |
| Category: Neurology | ||||||
| 01/26/2023 | Eli Lilly and Company | — | — | In-kind items and services | $2.80 | Research |
| Study: ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/04/2023 | Eli Lilly and Company | — | — | In-kind items and services | $260.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 12/09/2022 | EISAI INC. | — | Education | Cash or cash equivalent | $17.00 | General |
| 11/30/2022 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $133.95 | General |
| Category: Neurology | ||||||
| 10/17/2022 | EISAI INC. | — | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| 10/17/2022 | EISAI INC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 07/27/2022 | Eli Lilly and Company | — | — | In-kind items and services | $20.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 03/28/2022 | EISAI INC. | — | Travel and Lodging | Cash or cash equivalent | $120.00 | General |
| 03/28/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $49.76 | General |
| 03/28/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $44.11 | General |
| 03/28/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $35.82 | General |
| 03/28/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $12.47 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-045 | ACADIA Pharmaceuticals Inc | $86,516 | 8 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $5,359 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $4,697 | 2 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $2,575 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $260.00 | 1 |
| ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $2.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 105 | 105 | $40,600 | $19,865 |
| 2022 | 4 | 492 | 683 | $264,575 | $142,073 |
| 2021 | 6 | 649 | 904 | $335,500 | $183,015 |
| 2020 | 5 | 608 | 841 | $291,950 | $138,542 |
Total Patients
1,854
Total Services
2,533
Medicare Billing
$483,495
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 36 | 36 | $18,000 | $9,996 | 55.5% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 32 | 32 | $15,200 | $6,712 | 44.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 37 | $7,400 | $3,156 | 42.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 176 | 258 | $129,000 | $75,715 | 58.7% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2022 | 122 | 165 | $78,375 | $33,568 | 42.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 143 | 209 | $41,900 | $25,074 | 59.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 51 | 51 | $15,300 | $7,716 | 50.4% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Office | 2021 | 221 | 346 | $173,000 | $101,236 | 58.5% |
| 95957 | Digital analysis of electrical brain wave activity (eeg) | Office | 2021 | 123 | 167 | $79,325 | $33,236 | 41.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 179 | 255 | $51,000 | $33,191 | 65.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 67 | 67 | $20,100 | $10,631 | 52.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 24 | 33 | $5,775 | $3,170 | 54.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 36 | $6,300 | $1,551 | 24.6% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Office | 2020 | 240 | 363 | $181,500 | $95,146 | 52.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 207 | 310 | $54,250 | $21,097 | 38.9% |
| 95957 | Digital analysis of electrical brain wave activity (eeg) | Office | 2020 | 65 | 65 | $30,875 | $12,337 | 40.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 73 | 73 | $20,075 | $7,612 | 37.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 23 | 30 | $5,250 | $2,350 | 44.8% |
About Dr. Richard Holub, MD
Dr. Richard Holub, MD is a Neurology healthcare provider based in Albany, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497701635.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Holub, MD has received a total of $113,635 in payments from pharmaceutical and medical device companies, with $7,325 received in 2024. These payments were reported across 282 transactions from 31 companies. The most common payment nature is "" ($99,410).
As a Medicare-enrolled provider, Holub has provided services to 1,854 Medicare beneficiaries, totaling 2,533 services with total Medicare billing of $483,495. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Albany, NY
- Active Since 05/26/2006
- Last Updated 02/06/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1497701635
Products in Payments
- NUPLAZID (Drug) $86,835
- None (Drug) $2,025
- Leqembi (Drug) $420.49
- Briviact (Drug) $399.45
- GILENYA (Drug) $300.46
- LEMTRADA (Drug) $291.35
- Rebif (Biological) $231.19
- ADUHELM (Biological) $206.04
- APTIOM (Drug) $198.90
- NAMZARIC (Drug) $132.45
- GOCOVRI (Drug) $107.00
- RYTARY (Drug) $96.87
- Betaseron (Drug) $93.85
- ACTHAR (Biological) $90.39
- AMPYRA (Drug) $81.66
- OXTELLAR XR (Drug) $79.44
- NUEDEXTA (Drug) $77.98
- AUBAGIO (Drug) $75.40
- Xadago (Drug) $68.16
- INBRIJA (Drug) $66.34
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Albany
Charles Argoff, Md, MD
Neurology — Payments: $1.6M
Neurology $1.6M
Mrs. Angela Applebee, M.d, M.D
Neurology — Payments: $690,780
Neurology $690,780
Dr. Krupa Pandey, M.d, M.D
Neurology — Payments: $611,544
Neurology $611,544
Dr. Stanley Penc, Md Phd, MD PHD
Neurology — Payments: $552,076
Neurology $552,076
Dr. Timothy Lynch, Md, MD
Neurology — Payments: $273,946
Neurology $273,946
Dr. Jennifer Durphy, M.d, M.D
Neurology — Payments: $117,071
Neurology $117,071